STAT+: Pharmalittle: We’re reading about a PhRMA ad campaign aimed at 340B, sales of Novo’s obesity pill, and more
The Pharmaceutical Research and Manufacturers of America (PhRMA) is launching a seven-figure ad campaign targeting the 340B Drug Pricing Program, which requires drug manufacturers to provide discounts to healthcare providers serving low-income patients. Meanwhile, the FDA's rejection rate for cell and gene therapies has increased significantly, raising concerns within the industry about regulatory stability.
The FDA's rejection rate for cell and gene therapies has increased significantly from 18% to 38% over a 15-month period, indicating a growing regulatory challenge in this space. This rise in rejections poses a critical concern for companies in healthtech and biotech sectors focused on developing such therapies, highlighting the need for enhanced strategic planning to navigate regulatory hurdles.